Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.
Summary
The Executive Director, Insights and Analytics (ED I&A) is a strategic enterprise leader responsible for building, scaling, and leading Tango Therapeutics’ Insights and Analytics center of excellence. As Tango transitions from a research-stage biotech into a fully integrated commercial organization, this executive will define the enterprise-wide data, analytics, and insights strategy to support the successful launch and lifecycle management of our precision synthetic lethality oral medicines.
Reporting directly to the Chief Commercialization Officer (CCO), the ED of I&A will serve as a critical member of the Commercial Leadership Team and cross-functional strategy teams. This leader will act as an indispensable thought partner to executive leadership, translating complex data ecosystems into actionable insights that influence enterprise direction, optimize performance, and drive data-driven decision-making across Sales, Marketing, Market Access, Medical Affairs, and Finance. The ED of I&A is responsible for building and mentoring a high-performing leadership team encompassing critical functions across Market Research, Forecasting, and a Data & Advanced Analytics Center of Excellence (COE).
Your Role:
Cross-Functional Leadership & Strategic Integration
- Serve as a core member of cross-functional teams, acting as the strategic anchor for market analysis, competitive landscape evaluation, and commercial insights
- Partner closely with Medical Affairs, Market Access, Finance, Marketing, and Clinical Development to align on evidence needs, performance KPIs, and overarching corporate strategies
- Synthesize complex data into a clear overview of commercial strategy, opportunities, and risks for the Executive Leadership Team (ELT) and Board of Directors
Market Research & Competitive Intelligence
- Direct the Market Research function to build a best-in-class capability that generates deep insights from healthcare professionals (HCPs), patients, and payers to shape brand strategy and product positioning
- Establish a proactive competitive intelligence capability to continuously track the competitive landscape, clinical developments, reimbursement trends, and disruptive innovations within the oncology space
Forecasting & Demand Planning
- Provide strategic oversight in the development of robust global forecasting models for marketed products and pipeline assets
- Lead scenario planning, demand models, sensitivity analyses, and pipeline handover strategies to inform long-range planning, investment allocation, and launch readiness efforts
Data Strategy & Advanced Analytics (COE)
- Lead the Data & Advanced Analytics COE in developing the enterprise data strategy (acquisition, integration, governance, and quality), and driving the adoption of predictive modeling and AI-enabled decision-making
- Oversee the evaluation, procurement, and integration of commercial oncology data assets, including specialty pharmacy, claims, EHR, payer, and real-world evidence (RWE) sources
- Stand-up performance analytics and executive dashboarding capabilities, transitioning the organization from static reporting to dynamic, predictive, and action-oriented intelligence
What You Bring:
Education & Experience
- Bachelor’s degree required; advanced degree (MBA, MS, MPH, PharmD, PhD, or related discipline) strongly preferred
- 15+ years of progressive experience in pharmaceutical/biotech insights, analytics, forecasting, or related commercial operations roles
- Deep oncology expertise and a proven track record of leading analytics for oncology or specialty product launches
- Proven leadership track record of building, scaling, and developing high-performing analytics and insights organizations from the ground up
Core Competencies
- Deep understanding of the global and U.S. oncology market landscape, patient journeys, clinical treatment pathways, and competitive dynamics
- Expertise in pharmaceutical data sources (e.g., claims, EHR, specialty distribution data) and the analytic-to-business action process
- Exceptional executive presence and communication skills, with the demonstrated ability to influence C-level peers and effectively present data-driven narratives
- Strong managerial courage and a proven ability to attract, develop, and retain top analytic and data science talent
#LI-Hybrid
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Skills Required
- Bachelor's degree
- 15+ years of progressive experience in pharmaceutical or biotechnology insights, analytics, forecasting, or related commercial operations roles
- Deep oncology expertise and experience leading analytics for oncology or specialty product launches
- Experience building, scaling, and developing high-performing analytics and insights organizations
- Understanding of global and U.S. oncology markets, patient journeys, clinical treatment pathways, and competitive dynamics
- Expertise with pharmaceutical data sources, including claims, EHR, and specialty distribution data
- Executive presence and communication skills, including presenting data-driven narratives to C-level leaders
- Ability to attract, develop, and retain analytics and data science talent
- Advanced degree such as MBA, MS, MPH, PharmD, PhD, or related discipline
What We Do
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
.png)
